Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling.
Selcia drug discovery provides integrated drug discovery services to support academics, institutions, biotech and pharma companies. Selcia assist in grant applications; execute the medicinal chemistry to deliver the best drug candidates, provide supporting project management and primary pharmacology, to ensure project success.
Selcia radiolabelling specialises in 14C GMP radiolabelling and produces 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, microdosing, research and regulatory studies; and environmental fate studies.
The purity and structure of our products are assured by our internal MHRA GLP accredited analytical department with 500MHz, 400MHz & 300MHz NMRs, mass spec and separation specialists. The group are experts in problem resolution to ensure projects meet agreed milestones.
Areas of Expertise:
- Medicinal chemistry: Small molecules, macrocycles, natural product chemistry
- Disease expertise: Anti-infectives, inflammation, CNS, pain, metabolic
- Target classes: GPCRs, ion channels, enzymes, isomerases
- 14C Custom Radiosynthesis
- GMP Radiolabelled API for Clinical Trials
- GLP/GMP Analytics – GLP NMR
- Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds
Mr Dave RobertsBD Director Radiochemistry
Sphere Fluidics Ltd
Sphere Fluidics Limited is an innovative Life Sciences company which delivers miniaturised products, systems and collaboration services in field of single cell analysis.
Sphere’s core technology is in the field of high throughput Picodroplet generation and analysis and has significant patent portfolio that protects its core expertise. It enables ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes.
Uniquely, as well as allowing single cell studies, the systems enable the study of different, large biomolecules that interact with or are secreted by those single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology
Sphere Fluidics' technology enables diverse applications such as study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains.
Sphere Fluidics has established multiple commercial partnerships, received Venture Capital investment and with its founders the Company have received almost £10 million in science and business funding to date.
Rob MarchmontCommercial Director
David HolmesPrincipal Engineer
Sygnature Discovery Limited
Sygnature Discovery, founded in 2004 in Nottingham, UK, is a leading provider of integrated drug discovery services to pharmaceutical companies, biotechs and academics located in Europe and the USA. Through its unique ‘federated’ CRO model, Sygnature undertakes complete drug discovery programmes and hit finding, hit-to-lead and lead optimisation projects for its clients. The company employs 75 laboratory-based, industry-experienced PhD medicinal chemists, computational chemists and in vitro biologists.
Working within the highly-complex, competitive and fast-paced pharmaceutical and biotech sectors, Sygnature has developed a unique approach to offering a premium integrated drug discovery service – the delivery of in-depth, pharmaceutical industry-derived drug discovery expertise and flexible FTE-based resource housed in a ‘state-of-the-art’ R&D facility, but at a cost effective price. From the outset, Sygnature has operated a business whose primary focus has been value creation for its clients, through the application of drug discovery expertise, close working relationships and complete transparency.
To facilitate the delivery of top quality drug discovery services to its clients, Sygnature has strategic alliances with Cyprotex Discovery (ADME/toxicology), Saretius (pre-clinical pain/CNS and metabolic disease models), Pneumolabs (pre-clinical respiratory models), Horizon Discovery (X-ManTM isogenic cell lines), ChanTest (ion channel experts) and Proteros (X-ray protein structure analysis).
For more information, visit: www.sygnaturediscovery.com and www.integrateddrugdiscovery.com.
Synpromics is a life science company focused on synthetic biology. Our core proprietary technology enables the design of optimized Synthetic Promoters to more effectively and efficiently regulate gene expression throughout biotechnology applications. Via product-development and distribution partnerships, Synpromics will commercially apply our novel promoters to enhance and expedite life science R&D, improve biology-based production processes, advance agricultural biotech and progress personalized medicine.